UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

Lamivudine

In Vitro Substrates

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Km (μM)	Cell System	Reference
ABCG2	BCRP, MXR	216.5	MDCK-transfected cells	Kim, 2007
SLC22A1	OCT1	249	HEK293-OCT1	Jung, 2008
SLC22A1	OCT1	1250	CHO-OCT1	Minuesa, 2009
SLC22A2	OCT2	46.3	OCT2-expressing oocytes	Choi, 2012

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Ki (μM)	Substrate used	Cell System	Reference
SLC22A1	OCT1	Lamivudine	17		1-methyl-4-phenylpyridinium (MPP+)	HEK293-OCT1	Jung, 2008
ABCC2	MRP2, cMOAT	Lamivudine	>133		Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
ABCC3	MRP3	Lamivudine	>133		Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
ABCC4	MRP4	Lamivudine	>133		Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
SLC22A5	OCTN2	Lamivudine		2590	L-carnitine	MDCKII-hOCTN2	Diao, 2009
SLC22A5	OCTN2	Lamivudine		2590	L-carnitine	MDCKII-hOCTN2	Diao, 2010
ABCB11	BSEP	Lamivudine	>133		Taurocholate	Sf9 cell membrane vesicles	Morgan, 2013

No drug-drug interaction information.